Tags : Ubrogepant

Pharma

Allergan Announces Completion of UBR-MD-04 & 3110-105-002 Study for Treatment

Shots: The two pivotal study conducted for assessing ubrogepant (50/100) vs usual care & ubrogepant (100) vs PBO for 1year & 8 wks. respectively to treat migrane in adults, evaluating its safety, tolerability & hepatic safety UBR-MD-04 (N=1,254) & 3110-105-002(N=516) study results: 21,454 migraine attacks were treated with 31,968 doses of ubrogepant with mean number […]Read More